Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Rare Diseases

Leukemia

Leukemia, Hairy Cell

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hairy Cell Leukemia

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Rituximab

Vemurafenib

Antineoplastic Agents, Immunological

Immunologic Factors

Protein Kinase Inhibitors

Enzyme Inhibitors

Eligible patients will receive vemurafenib at a dose of 240 mg orally twice daily (b.i.d.) continuously for 8 weeks. Rituximab 375 mg/m2 will be administered every 2 weeks for a total of 16 weeks. The entire duration of treatment will be 16 weeks.

Vemurafenib 960 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib

Low dose vemurafenib plus rituximab

Alan Saven, MD

David J Hermel, MD

The current standard-of-care for Hairy Cell Leukemia involves chemotherapy, with agents such as cladribine or pentostatin. Chemotherapy is associated with infection, low blood counts and predisposition to future cancers. This study tests a new yet previously validated drug combination for the treatment of hairy cell leukemia. The treatment involves 8 weeks of treatment with an oral drug called vemurafenib and 8 doses of an intravenous medication called rituximab. The goal of this study is to see whether this treatment is better tolerated and more effective than the currently used treatment in this disease. In addition, this study uses a lower dose of vemurafenib than previous studies have used, with the goal of minimizing side effects from this medication.

This is a single-center, open label, single arm, investigator-initiated phase II trial of the oral BRAF inhibitor, vemurafenib, plus rituximab in patients with previously untreated or relapsed and refractory HCL. Eligible patients will receive vemurafenib at a dose of 240 mg orally twice daily (b.i.d.) continuously for 8 weeks. Rituximab 375 mg/m2 will be administered concomitantly with vemurafenib every 2 weeks from the first day of treatment. After completion of vemurafenib, the patient will receive rituximab 375 mg/m2 every 2 weeks for a total of 8 weeks. The entire duration of treatment will be 16 weeks. Six months after the initiation of the treatment, a bone marrow aspirate and biopsy will be performed for assessment of response and evaluation of minimal residual disease (MRD).

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the Front-line and Relapsed/Refractory Treatment of Hairy Cell Leukemia

Plan to publish aggregate data in manuscript

Resolution of cytopenias and splenomegaly

At the time of bone marrow assessment by testing for BRAFV600E mutation status

Reapperance of Hairy-Cell related cytopenia

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia	NCT05388123	Hairy Cell Leuk...	Low dose vemura...	18 Years - 90 Years	Scripps Health
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia	NCT05388123	Hairy Cell Leuk...	Low dose vemura...	18 Years - 90 Years	Scripps Health

Spots Global Cancer Trial Database for low dose vemurafenib plus rituximab